Key Findings
Century Therapeutics has announced groundbreaking preclinical data for CNTY-813, its iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0 immune evasion technology for Type 1 Diabetes (T1D), at the American Diabetes Association (ADA) 2026 annual meeting. The presented data demonstrated durable glucose control in preclinical models for over eight months and robust immune evasion under alloimmune pressure without the need for immunosuppressive agents. Furthermore, a scalable manufacturing process has been established for Phase 1 clinical trial supply, strongly suggesting CNTY-813’s potential to provide a functional cure for Type 1 Diabetes.
Technical and Clinical Details
CNTY-813 consists of iPSC-derived islet-like cells engineered using Century Therapeutics’ proprietary Allo-Evasion™ 5.0 gene-editing platform. This platform is designed to modulate the expression of major histocompatibility complex (MHC) class I and II, thereby evading immune responses from T cells and NK cells against non-self-cells. Preclinical studies in humanized mouse and large animal models demonstrated that CNTY-813 cells maintained stable insulin secretion and normalized blood glucose levels for over eight months post-transplantation. Notably, immune evasion was effective even without the administration of immunosuppressive drugs, preventing allograft rejection. On the manufacturing front, a large-scale culture process compliant with GMP standards has been established, ensuring efficient production of sufficient quantities of cells with consistent quality. This is a crucial aspect for both clinical trials and future commercialization.
Background and Industry Context
Type 1 Diabetes is a chronic autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas, necessitating lifelong insulin replacement therapy. Current treatments manage blood glucose levels but do not offer a cure and carry risks of severe complications. Islet transplantation can be curative, but is hampered by donor scarcity and the requirement for lifelong immunosuppression. iPSC-derived islet replacement therapies, such as CNTY-813, offer an unlimited cell source and the potential to reduce or eliminate the need for immunosuppressants through immune evasion technologies, presenting a revolutionary solution to these challenges. Given the difficulty of achieving a functional cure with existing therapies, the progress of CNTY-813 offers substantial hope to patients and the medical community.
Strategic Significance and Outlook
The preclinical data for CNTY-813, demonstrating durable glucose control, robust immune evasion, and a scalable manufacturing process, holds the potential to be a significant breakthrough in Type 1 Diabetes treatment. Based on these achievements, Century Therapeutics plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q4 2026. Following IND approval, Phase 1 clinical trials for CNTY-813 will commence to evaluate its safety and efficacy in humans. Successful development of this program is anticipated to dramatically improve the quality of life for T1D patients, contributing significantly to the realization of a functional cure that liberates them from insulin dependence.
Comments